



Tysabri (for Maryland only)

Prior Authorization Request

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect[®] 1-800-237-2767.

Patient's Name:Patient's ID:Physician's Name:		Date: Patient's Date of Birth: NPI#: Physician Office Fax:		
Additional Demographic Information:				
	Patient Weight:kg			
	Patient Height:ftinches			
<u>Cr</u> :	iteria Questions: Has the patient been diagnosed with any of the following ☐ Moderately to severely active Crohn's disease (CD) ☐ Relapsing form of multiple sclerosis ☐ Primary progressive multiple sclerosis (PPMS) ☐ Other			
2.	What is the ICD-10 code?			
3.	Would the prescriber like to request an override of the st	ep therapy requirement? \square Yes \square No If No, skip to #6		
4.	Has the member received the medication through a pharmacy or medical benefit within the past 180 days? Yes No ACTION REQUIRED: Please provide documentation to substantiate the member had a prescription paid for within the past 180 days (i.e. PBM medication history, pharmacy receipt, EOB etc.)			
5.	Is the medication effective in treating the member's condition form in its entirety.	lition?		
Complete the following questions if patient has Crohn's disease.				
6.	Has the patient received any of the following medication the previous 120 days? <i>If Yes, please specify the most re</i> ☐ Tysabri ☐ Cimzia ☐ Humira ☐ Inflectra ☐ Ren			
7.	If patient is continuing on therapy, how long has the patient been receiving the requested medication? weeks / months (circle one) If the patient has NOT received TYSABRI in a paid claim through a pharmacy or medical benefit in the previous 120 days, skip to #9.			
0				
8.	Has the patient achieved or maintained positive clinical ror improvement in signs and symptoms? Yes No	response to treatment as evidenced by low disease activity of No further questions		
	e: This fax may contain medical information that is privileged and confidential and			

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

immediately notify the sender by telephone and destroy the original fax message. Tysabri CareFirst – 5/2017.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. ®' Registered trademark of CareFirst of Maryland, Inc.

rre	escriber or Authorized Signature	Date (mm/dd/yy)
X_		Date (con 1111)
	attest that this information is accurate and true, and the formation is available for review if requested by CVS	
12.	Does the patient have a contraindication or intolerance to a (e.g., Cimzia, Humira, Inflectra, Remicade?	Io
11.	Has the patient had an inadequate response to a TNF inhib Humira, Inflectra, Remicade)? Yes No If Yes, indicate the previous treatment regimen and no full Yes.	
	☐ Contraindication:	
	☐ Intolerance:	
10.	Does the patient have a contraindication or intolerance to a <i>If Yes, indicate the medication and contraindication or in</i> ☐ Medication:	ntolerance.
9.	Has the patient tried and had an inadequate response to at [Azasan, Imuran], budesonide [Entocort EC], ciprofloxaci Lialda], mercaptopurine [Purinethol], methylprednisolone prednisone, sulfasalazine [Azulfidine, Sulfazine], rifaximin If Yes, indicate the previous treatment regimen and skip in the sulface of the previous treatment regimen and skip in the sulface of the previous treatment regimen and skip in the sulface of the previous treatment regimen and skip in the sulface of the	n [Cipro], mesalamine [Asacol, Delzicol, Pentasa, [Solu-Medrol], methotrexate, metronidazole [Flagyl], n [Xifaxan])?